The Future of Treating Psoriasis and Psoriatric Arthritis

 

A supplement to Skin & Allergy News supported by an unrestricted educational grant from Amgen and Wyeth.
Highlights of presentations made at the 26thAnnual Hawaii Dermatology Seminar.

?Contents
?Target Audience
?Educational Needs
?Learning Objectives
?Accreditation

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 11.

Contents

Introduction: TNF Inhibition

Mark G. Lebwohl, MD
Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, N.Y.
Financial support: Wyeth and Immunex Corporation. Consultant: Immunex. Discusses unlabeled use of etanercept for the treatment of psoriasis.

Safety and Efficacy of TNF Inhibition

Mark C. Genovese, MD
Assistant Professor of Medicine
Immunology and Rheumatology
Stanford University Medical Center
Stanford, CA
Clinical Grants: Immunex Corporation; Consultant: Wyeth

TNF Inhibition for the Treatment of Psoriatic Arthritis

Alice B. Gottlieb, MD, PhD
W.H. Conzen Chair in Clinical Pharmacology
Professor of Medicine
University of Medicine and Dentistry of New Jersey
Robert Wood Johnson Medical School
New Brunswick, N.J.
Clinical Grants: Wyeth and Immunex Corporation; Consultant: Wyeth and Immunex Corporation. Discusses unlabeled use of etanercept for the treatment of psoriasis.

The Role of TNF Inhibition in the Treatment of Psoriasis

Mark G. Lebwohl, MD
Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, N.Y.
Financial Support: Wyeth and Immunex Corporation. Consultant: Immunex. Discusses unlabeled use of etanercept for the treatment of psoriasis.
Target Audience

This activity has been developed for dermatologists and other health care professionals involved in the treatment of psoriasis and psoriatic arthritis.

Educational Needs

It is now known that tumor necrosis factor (TNF) plays a role in the development of psoriasis and psoriatic arthritis. Clinical studies have demonstrated that inhibition of TNF is a safe and effective strategy for treating selected patients. The TNF inhibitor, etanercept, previously approved for the treatment of adult and juvenile rheumatoid arthritis, recently was approved by the Food and Drug Administration for the treatment of psoriatic arthritis. In addition, the results of recent clinical trials have shown that anti-TNF therapy also has promise as treatment for the skin lesions of psoriasis. This activity provides dermatologists with up-to-date information on the efficacy and safety of etaneercept in the treatment of psoriatic arthritis and psoriasis.

Learning Objectives

Upon completion of this program, participants should be able to:

? Explain the rationale for the use of TNF inhibitors in the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis and psoriatic arthritis.

? Discuss the accumulated safety data concerning etanercept from clinical trials and from postmarketing surveillance.

? Describe the efficacy and safety of etanercept in patients with psoriatic arthritis.

? Describe the efficacy and safety in patients with cutaneous psoriasis.

Accreditation

The American Academy of Dermatology certifies that this educational activity has been recognized for 1 hour of AAD Category 1 credit and may be used toward the American Academy of Dermatology's Continuing Medical Education Award. This program was developed in accordance with the Accreditation Council for Continuing Medical Education guidelines. Term of approval: July 2002-June 2003.

 

---